Pemigatinib not checked
Incyte Corporation · INCB054828 · NCB054828
FollowEvery change as it happens, and a Monday email
Trials
8 active
21 in total · 11 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “Pemigatinib at the protocol-defined dose administered orally once daily in 21-day cycles with 14 days on therapy followed by 7 days off therapy.”In the company’s words, NCT07862998 on ClinicalTrials.gov
- Tested for
- Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
- Main trialPhase 2
- “The purpose of this study is to confirm the efficacy and safety of pemigatinib in participants with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 fusion or rearrangements after at least 1 prior line of systemic therapy.”In the company’s words, NCT07862998 on ClinicalTrials.gov
- Other names
- INCB054828 · Pemazyre · NCB054828 · INCB 54828
Coming up1
- 25 Feb 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 25 Feb 2031 | A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy | |
| Phase 3Terminated | 7 Jul 2025 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | |
| Phase 2Terminated | 12 Jun 2020 | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | |
| Phase 2Terminated | 18 Apr 2021 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | |
| Phase 2Completed | 1 Feb 2022 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | |
| Phase 2Completed | 1 Feb 2022 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | |
| Phase 2Terminated | 29 Mar 2022 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | |
| Phase 2Completed | 16 Aug 2023 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | |
| Phase 2Terminated | 11 Apr 2024 | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | |
| Phase 2Completed | 30 Oct 2024 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | |
| Phase 2Terminated | 17 Dec 2024 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | |
| Phase 2Completed | 29 May 2026 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | |
| Phase 1/2Terminated | 17 Dec 2021 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | |
| Phase 2Authorised | not given | PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling | |
| Phase 2Ended | not given | PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements | |
| Phase 2Authorised | not given | AcSé pemigatinib: Phase II trial evaluating the efficacy of pemigatinib in patients with recurrent and/or metastatic solid tumor harboring a FGFR alteration | |
| Phase 2Authorised | not given | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile | |
| Phase 2Authorised | not given | TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026